The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, enhances antitumor efficacy of paclitaxel and Nab-paclitaxel in TP53 wild-type MCF-7 breast cancer models

被引：0
|
作者：
Pairawan, S. S.
Yuca, E.
Evans, K.
Annis, A.
Narasimhan, N.
Sutton, D.
Carvajal, L. A.
Ren, J-G
Santiago, S.
Guerlavais, V.
Akcakanat, A.
Tapia, C.
Dumbrava, E. E. Illeana
Aivado, M.
Meric-Bernstam, F.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Aileron Therapeut, Cambridge, MA USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P6-20-11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-20-11
引用
收藏
页数：2
相关论文
共 10 条
  • [1] First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
    Seyed Pairawan
    Ming Zhao
    Erkan Yuca
    Allen Annis
    Kurt Evans
    David Sutton
    Luis Carvajal
    Jian-Guo Ren
    Solimar Santiago
    Vincent Guerlavais
    Argun Akcakanat
    Coya Tapia
    Fei Yang
    Priya Subash Chandra Bose
    Xiaofeng Zheng
    Ecaterina Ileana Dumbrava
    Manuel Aivado
    Funda Meric-Bernstam
    [J]. Breast Cancer Research, 23
  • [2] First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
    Pairawan, Seyed
    Zhao, Ming
    Yuca, Erkan
    Annis, Allen
    Evans, Kurt
    Sutton, David
    Carvajal, Luis
    Ren, Jian-Guo
    Santiago, Solimar
    Guerlavais, Vincent
    Akcakanat, Argun
    Tapia, Coya
    Yang, Fei
    Bose, Priya Subash Chandra
    Zheng, Xiaofeng
    Dumbrava, Ecaterina Ileana
    Aivado, Manuel
    Meric-Bernstam, Funda
    [J]. BREAST CANCER RESEARCH, 2021, 23 (01)
  • [3] Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
    Saleh, Mansoor N.
    Patel, Manish R.
    Bauer, Todd M.
    Goel, Sanjay
    Falchook, Gerald S.
    Shapiro, Geoffrey, I
    Chung, Ki Y.
    Infante, Jeffrey R.
    Conry, Robert M.
    Rabinowits, Guilherme
    Hong, David S.
    Wang, Judy S.
    Steidl, Ulrich
    Naik, Gurudatta
    Guerlavais, Vincent
    Vukovic, Vojislav
    Annis, D. Allen
    Aivado, Manuel
    Meric-Bernstam, Funda
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5236 - 5247
  • [4] Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type
    Sallman, David A.
    Borate, Uma
    Cull, Elizabeth H.
    Donnellan, William B.
    Komrokji, Rami S.
    Steidl, Ulrich G.
    Corvez, Maria M.
    Payton, Marie
    Annis, D. Allen
    Pinchasik, Dawn
    Aivado, Manuel
    Verma, Amit
    [J]. BLOOD, 2018, 132
  • [5] Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (vol 27, pg 5236, 2021)
    Saleh, Mansoor N.
    Patel, Manish R.
    Bauer, Todd M.
    Goel, Sanjay
    Falchook, Gerald S.
    Shapiro, Geoffrey I.
    Chung, Ki Y.
    Infante, Jeffrey R.
    Conry, Robert M.
    Rabinowits, Guilherme
    Hong, David S.
    Wang, Judy S.
    Steidl, Ulrich
    Walensky, Loren D.
    Naik, Gurudatta
    Guerlavais, Vincent
    Vukovic, Vojislav
    Annis, D. Allen
    Aivado, Manuel
    Meric-Bernstam, Funda
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (02) : 429 - 429
  • [6] Harnessing the anticancer activity of the stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, using rational combination strategies for breast cancer and other malignancies
    Annis, A.
    Ren, J. G.
    Carvajal, L. A.
    Santiago, S.
    Narasimhan, N.
    Sutton, D.
    Pairawan, S. S.
    Guerlavais, V.
    Meric-Bernstam, F.
    Aivado, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 103 : E143 - E144
  • [7] In Vitro andpre-Clinical In Vivo evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53 -Wild-Type T-Cell Lymphomas That Are Targetable with the α-Helical p53 Stapled Peptide Alrn-6924
    Koch, Raphael
    Christie, Amanda L.
    Yoshida, Noriaki
    Ng, Samuel Y.
    Shigemori, Kay
    Morrow, Sara N.
    Van Scoyk, Alexandria
    Horwitz, Steven M.
    Jacobsen, Eric
    Santiago, Solimar
    Ren, Jian-Guo
    Guerlavais, Vincent
    Annis, D. Allan
    Aivado, Manuel A.
    Weinstock, David M.
    [J]. BLOOD, 2017, 130
  • [8] Phase 2a study of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of wild-type TP53 in patients with peripheral t-cell lymphoma
    Payton, M.
    Pinchasik, D.
    Mehta, A.
    Goel, S.
    Zain, J. M.
    Sokol, L.
    Jacobsen, E.
    Patel, M. R.
    Horwitz, S. M.
    Meric-Bernstam, F.
    Shustov, A.
    Weinstock, D.
    Aivado, M.
    Annis, D. A.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [9] Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML)
    Nimmagadda, Subbaiah Chary
    Patnana, Pradeep Kumar
    Budde, Paulina Marie
    Ahmed, Helal
    Covey, Todd
    Krejsa, Cecile
    Rothbaum, Wayne
    Von Bubnoff, Nikolas
    Khandanpour, Cyrus
    [J]. BLOOD, 2023, 142
  • [10] Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells
    Fan, Yangwei
    Ma, Ke
    Jing, Jiayu
    Wang, Chuying
    Hu, Yuan
    Shi, Yu
    Li, Enxiao
    Geng, Qianqian
    [J]. JOURNAL OF CANCER, 2020, 11 (01): : 25 - 40
1